Form 4: IMMUNIC CEO Daniel Vitt Boosts Stake with Significant Stock Purchase and Option Grant

IMMUNIC, Inc. CEO and Director Daniel Vitt has increased his beneficial ownership in the company through a direct purchase of common stock and the acquisition of substantial stock options.

Summary

• Daniel Vitt, CEO and Director of IMMUNIC, INC. (IMUX), acquired 15,000 shares of common stock directly on June 4, 2025, at a price of $0.77 per share.
• The purchase price was converted from Euros, with Euro 1.00 equaling U.S. dollar 1.1384 on the transaction date.
• Following this transaction, Daniel Vitt directly owns 29,000 shares of common stock.
• Additionally, 362,877 shares of common stock are indirectly owned by Listrax UG (haftungsbeschrankt), where Daniel Vitt serves as Managing Director and exercises voting and dispositive power.
• On June 5, 2025, Mr. Vitt was granted 1,535,000 stock options with an exercise price of $0.7729 per share.
• These stock options have an expiration date of June 5, 2035.
• The vesting schedule for the options is 25% on the first anniversary of the grant date (June 5, 2026), with the remaining portion vesting in equal monthly increments over the subsequent 36 months.

Sentiment

Score: 8

Explanation: The sentiment is positive due to the CEO's direct stock purchase and substantial option grant, indicating strong insider confidence in the company's valuation and future prospects.

Positives

• The direct purchase of 15,000 shares by CEO Daniel Vitt signals management's confidence in the company's future prospects.
• The acquisition of 1,535,000 stock options aligns the CEO's long-term incentives with shareholder value creation.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Management Comments

• "/s/ Daniel Vitt" (Signature confirming the filing).

Industry Context

This insider transaction reflects a direct investment by the CEO in the company's equity, which is a common occurrence across industries and often interpreted as a sign of confidence in the company's future performance within its specific sector.

Related Party Transactions

• Daniel Vitt indirectly owns 362,877 shares of common stock through Listrax UG (haftungsbeschrankt), where he is the Managing Director and exercises control over the shares.

Stakeholder Impact

• Shareholders may view the CEO's increased stake as a positive signal, potentially boosting investor confidence and the company's stock price.
• Employees may perceive this as a sign of stability and positive outlook from leadership.

Key Dates

Recommendation

Keywords

IMMUNIC, IMUX, Daniel Vitt, SEC Form 4, Insider Trading, Stock Purchase, Stock Options, Beneficial Ownership, CEO, Director, Equity Compensation